Theriva Biologics, Inc. (TOVX) Financial Ratios
32 years of historical data (1993–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.01
↓-100% vs avg
5yr avg: 9.55
30Y Low0.1·High195.4
ROE
↑
-87.3%
↑-37% vs avg
5yr avg: -63.9%
30Y Low-400%·High-33%
Debt/EBITDA
N/A
—
5yr avg: N/A
30Y Low0.1·High0.2
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Theriva Biologics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2M | $2M | $7M | $7M | $829M | $182M | $208M | $87M | $1.6B | $1.8B | $4.6B |
| Enterprise Value | $-8148954 | $-7684780 | $-14096990 | $-33134167 | $764M | $176M | $194M | $58M | $1.6B | $1.8B | $4.6B |
| P/E Ratio → | -0.01 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.01 | 0.12 | 0.17 | 0.13 | 12.68 | 34.62 | 18.14 | 3.30 | — | 798.50 | 307.65 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -87.3% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -87.3% | -87.3% | -38.9% | -32.8% | -40.4% | -120.0% | -80.7% | -116.0% | — | -316.0% | -356.2% |
| ROA | -56.6% | -56.6% | -28.9% | -27.7% | -36.2% | -78.3% | -64.6% | -54.6% | -73.4% | -102.2% | -175.0% |
| ROIC | -142.7% | -142.7% | -97.0% | -230.1% | — | — | — | — | — | — | — |
| ROCE | -69.1% | -69.1% | -37.8% | -32.8% | -39.5% | -116.8% | -80.9% | -98.2% | -445.5% | -435.9% | -330.1% |
Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $12M exceeds total debt of $2M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.08 | 0.08 | 0.05 | 0.03 | 0.02 | 0.09 | 0.06 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.53 | -0.53 | -0.74 | -1.01 | -1.09 | -1.25 | -1.09 | — | -8.47 | -1.39 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($12M) exceeds total debt ($2M)
Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Theriva Biologics, Inc.'s current ratio of 2.15x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 6.45x to 2.15x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.15 | 2.15 | 4.07 | 6.45 | 19.37 | 2.67 | 3.11 | 8.72 | 1.83 | 1.09 | 1.95 |
| Quick Ratio | 2.15 | 2.15 | 4.07 | 6.45 | 19.37 | 2.67 | 3.11 | 8.72 | 1.83 | 1.09 | 1.95 |
| Cash Ratio | 1.53 | 1.53 | 3.44 | 5.92 | 18.94 | 2.10 | 2.85 | 8.55 | 1.75 | 0.96 | 1.34 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Theriva Biologics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 4.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 4.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $1M | $644280 | $613090 | $12M | $2M | $2M | $623244 | $355331 | $269397 | $230584 |
Peer Comparison
Compare TOVX with 7 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 TOVXYou | $2M | -0.0 | — | — | — | — | -87.3% | -142.7% | — |
 MCRB | $77M | -0.5 | — | — | — | — | 1.0% | -180.9% | — |
 PHGE | $76M | -2.9 | — | — | — | — | -130.2% | -305.2% | — |
 ARMP | $40M | -21.0 | — | — | -565.4% | -820.2% | — | -44.2% | — |
 EVGN | $7M | -0.3 | — | — | 39.8% | -255.4% | -75.8% | -102.4% | — |
 SYBX | $7M | -0.3 | — | — | 100.0% | -511875.0% | -84.3% | -205.7% | — |
 AZTR | $2M | -0.1 | — | — | — | — | -0.6% | -0.8% | — |
 ELAB | $766221 | -0.0 | — | — | 72.8% | -75.7% | -119.1% | -82.7% | — |
| Healthcare Median | — | 23.3 | 13.6 | 18.1 | 66.0% | -6.6% | -36.9% | -13.6% | 3.0 |
Peers based on L4 peer group classification. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
See TOVX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TOVX Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare TOVX vs MCRB
See how TOVX stacks up against sector leader Seres Therapeutics, Inc..
Start ComparisonFrequently Asked Questions
What is Theriva Biologics, Inc.'s P/E ratio?
Theriva Biologics, Inc.'s current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
What is Theriva Biologics, Inc.'s ROE?
Theriva Biologics, Inc.'s return on equity (ROE) is -87.3%. The historical average is -137.1%.
Is TOVX stock overvalued?
Based on historical data, Theriva Biologics, Inc. is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.